This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Japan Tobacco Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Ryuhei Okura: Innovator in Janus Kinase Inhibitors
Introduction
Ryuhei Okura is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of Janus kinase inhibitors. His work has implications for various therapeutic applications.
Latest Patents
Ryuhei Okura holds 1 patent related to his innovative research. His patent focuses on crystalline forms of a Janus kinase (JAK) inhibitor, specifically the compound 3-((3S,4R)-3-methyl-6-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, also referred to as Compound A. This invention encompasses not only the crystalline forms but also the compositions, methods of preparation, methods of use, and methods of quantitation.
Career Highlights
Ryuhei Okura is associated with Japan Tobacco Inc., where he has been able to leverage his expertise in medicinal chemistry. His work has contributed to advancements in drug development and therapeutic strategies.
Collaborations
Throughout his career, Ryuhei has collaborated with esteemed colleagues such as Yukihiro Kamiya and Noriaki Shimoyama. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Ryuhei Okura's contributions to the field of Janus kinase inhibitors highlight his role as a significant inventor in the pharmaceutical industry. His innovative work continues to pave the way for future advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile